This technology relates to a composition for diagnosing diabetes and a method for providing information, which includes a substance for detecting specific metabolites in the tears of diabetic patients.
Conventional diabetes diagnosis relies on invasive methods such as blood sampling, causing inconvenience for early and self-diagnosis. Consequently, there has been a demand for simple and non-invasive diagnostic tools.
This technology identifies tear metabolite biomarkers through GC/TOF MS analysis, showing increased levels of threonine, mannose, sorbitol, etc., and decreased levels of 1,5-anhydroglucitol, beta-alanine, etc. This enables accurate and non-invasive diagnosis of diabetes using only tears.
WO2022-186652A1